North American Scientific's NOMOS Radiation Oncology division has introduced BATCAM Multi-probe, its new image-guided radiation therapy (IGRT) solution, at the 49th Annual Meeting of the American Association of Physics in Medicine (AAPM). The BATCAM Multi-probe received FDA 510(k) approval in July 2007.
BATCAM Multi-probe integrates a new multi-probe capable ultrasound system into the company's core IGRT product, BATCAM. The new system features an updated abdominal ultrasound probe featuring colour doppler ultrasound enabling IGRT for liver and pancreas treatments in addition to prostate and gynaecology. Optional add-ons to the system include a bi-planar rectal probe for prostate volume studies and prostate brachytherapy, and a wideband, linear probe for verification of Accelerated Partial Breast Irradiation (APBI) brachytherapy devices such as ClearPath.
"BATCAM Multi-probe is a crucial advancement in providing improved imaging and value to clinicians seeking IGRT solutions and offers greater utility in addition to expanded clinical IGRT use," said John Rush, President and CEO of North American Scientific. "Facilities that adopt this new technology will quickly realise the benefits of a system that can be applied to a wide variety of applications throughout their cancer clinic. We are particularly pleased to present a product that is equipped to provide support for our brachytherapy business, including our Prospera brachytherapy seeds and the ClearPath devices which we plan to launch commercially later this year."
